Preliminary data demonstrated that A2AR inhibitor (CPI-444), as a single agent and in combination with the anti-PD-L1 mAb (Atezolizumab®) is well-tolerated and shows anti-tumor activity in refractory renal cancer and NSCLC cohorts (89). This evidence concerns the gene ADORA2A and neoplasm.